Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Personalis Inc PSNL

Technology Scientific & Technical Instruments
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome... see more

Recent & Breaking News (NDAQ:PSNL)

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

Business Wire 4 hours ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 4 days ago

Personalis Reports First Quarter 2024 Financial Results

Business Wire 13 days ago

Personalis to Announce First Quarter 2024 Financial Results

Business Wire April 24, 2024

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Business Wire March 28, 2024

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Business Wire March 28, 2024

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Business Wire March 26, 2024

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 19, 2024

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire February 28, 2024

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results

Business Wire February 14, 2024

Personalis to Participate at Upcoming Investor Conferences

Business Wire January 31, 2024

Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology

Business Wire January 30, 2024

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 17, 2024

Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay

Business Wire January 16, 2024

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

Business Wire January 5, 2024

Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives

Business Wire December 4, 2023

Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing

Business Wire November 28, 2023

Personalis Reports Third Quarter 2023 Financial Results

Business Wire November 7, 2023

Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

Business Wire October 26, 2023

Personalis to Announce Third Quarter 2023 Financial Results

Business Wire October 24, 2023